Previous 10 | Next 10 |
MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) , (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced t...
The European Commission (EC) granted orphan drug designation to Panbela Therapeutics' ( NASDAQ: PBLA ) ivospemin to treat a type of pancreatic cancer. The EC adopted the positive opinion issued by a panel of the European Medicines Agency (EMA) to designate the s...
MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for Or...
Panbela Therapeutics ( NASDAQ: PBLA ) is set to execute a 1-for-40 reverse split of its common stock to aid compliance with Nasdaq's continued listing requirements. The common stock will trade on a post-split basis at the beginning of trading on January 13, 2023 under the existing...
MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announce...
Panbela Therapeutics ( NASDAQ: PBLA ) is trading ~19% higher after it begun a Phase II study to test CPP-1X-T (Eflornithine tablets) for type 1 diabetes, in collaboration with Indiana University School of Medicine. The study will test patients with recent onset type ...
MINNEAPOLIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it has commenced a Phase II double-blind, randomized st...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers for Tuesday! Moving stocks this morning are acquisition deals, clinical trial data, a failed...
A committee of the European Medicines Agency (EMA) issued a positive opinion on Panbela Therapeutics' ( NASDAQ: PBLA ) application for orphan designation for ivospemin (SBP-101) to treat a type of pancreatic cancer. The EMA's Committee for Orphan Medicinal Prod...
MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pa nbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for ...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...